Faes Farma S.A. Logo

Faes Farma S.A.

ISIN: ES0134950F36 | Ticker: FAE | LEI: 959800FXZQY7U3P1G969
Sector: Health CareSub-Industry: Pharmaceuticals
Country: Spain

About Faes Farma S.A.

Company Description

Founded in 1933, FAES FARMA is a Spanish pharmaceutical company with extensive international experience that researches, produces and markets pharmaceutical products and raw materials, exporting them to many countries.

The identity of the company is defined by an unwavering search of excellence, the constant pursuit of a máximum pharmacological quality of all its products and the consequent effort to always offer highly effective solutions for patients.

FAES FARMA operates in many countries, employing more than 1680 people. Its headquarters, manufacturing and R & D center is located in Leioa (Bizkaia). FAES FARMA has also facilities in Madrid and subsidiaries in Portugal, Laboratorios Vitoria, in Barcelona Diafarm Laboratories and also in Italy, France, Chile, Mexico, Colombia, Peru, Ecuador and Nigeria. FAES FARMA has nutrition and animal health companies (FARM Faes) such as Ingaso Farm and Tecnovit.

Year founded

1933

Served area

Worldwide

Headcount

1,680

Headquarters

Av Autonomia 10, 48940 Leioa – Spain

Financial statements

Download as Excel
Line item in (eur) 01.01.2019 01.01.2020 02.01.2020 01.01.2021 02.01.2021 01.01.2022 02.01.2022 01.01.2023
Assets N/A 493,673,000.00 N/A 581,517,000.00 N/A 645,114,000.00 N/A 725,670,000.00
Noncurrent Assets N/A 270,684,000.00 N/A 291,510,000.00 N/A 351,403,000.00 N/A 412,459,000.00
Property Plant And Equipment N/A 78,703,000.00 N/A 91,254,000.00 N/A 136,100,000.00 N/A 200,141,000.00
Investment Property N/A 1,550,000.00 N/A 1,550,000.00 N/A 1,550,000.00 N/A 1,550,000.00
Deferred Tax Assets N/A 14,133,000.00 N/A 28,854,000.00 N/A 26,474,000.00 N/A 21,286,000.00
Other Noncurrent Financial Assets N/A 460,000.00 N/A 338,000.00 N/A 990,000.00 N/A 5,132,000.00
Current Assets N/A 222,989,000.00 N/A 290,007,000.00 N/A 293,711,000.00 N/A 313,211,000.00
Inventories N/A 71,454,000.00 N/A 91,591,000.00 N/A 107,451,000.00 N/A 115,000,000.00
Trade And Other Current Receivables N/A 97,352,000.00 N/A 105,280,000.00 N/A 112,852,000.00 N/A 114,111,000.00
Other Current Financial Assets N/A 1,330,000.00 N/A 1,926,000.00 N/A 3,154,000.00 N/A 17,689,000.00
Cash and cash equivalents N/A 52,853,000.00 52,853,000.00 91,210,000.00 91,210,000.00 70,254,000.00 70,254,000.00 66,411,000.00
Equity And Liabilities N/A 493,673,000.00 N/A 581,517,000.00 N/A 645,114,000.00 N/A 725,670,000.00
Equity 360,154,000.00 413,654,000.00 472,877,000.00 472,877,000.00 537,348,000.00 537,348,000.00 N/A 602,279,000.00
Issued Capital N/A 27,815,000.00 N/A 28,524,000.00 N/A 29,742,000.00 N/A 31,078,000.00
Retained Earnings N/A 90,632,000.00 N/A 104,268,000.00 N/A 127,012,000.00 N/A 147,532,000.00
Share Premium N/A 1,460,000.00 N/A 1,460,000.00 N/A 1,460,000.00 N/A 1,460,000.00
Treasury Shares N/A 5,264,000.00 N/A 5,264,000.00 N/A 5,264,000.00 N/A 5,264,000.00
Other Reserves N/A 298,323,000.00 N/A 344,896,000.00 N/A 385,922,000.00 N/A 442,877,000.00
Equity Attributable To Owners Of Parent N/A 412,968,000.00 N/A 471,395,000.00 N/A 535,810,000.00 N/A 601,076,000.00
Noncontrolling Interests N/A 686,000.00 N/A 1,482,000.00 N/A 1,538,000.00 N/A 1,203,000.00
Liabilities N/A 80,019,000.00 N/A 108,640,000.00 N/A 107,766,000.00 N/A 123,391,000.00
Noncurrent Liabilities N/A 7,740,000.00 N/A 23,955,000.00 N/A 28,459,000.00 N/A 28,963,000.00
Noncurrent Provisions N/A 683,000.00 N/A 803,000.00 N/A 957,000.00 N/A 1,022,000.00
Noncurrent Government Grants N/A 187,000.00 N/A 187,000.00 N/A 157,000.00 N/A 35,000.00
Deferred Tax Liabilities N/A N/A N/A 17,367,000.00 N/A 21,699,000.00 N/A 19,742,000.00
Other Noncurrent Financial Liabilities N/A 3,569,000.00 N/A 3,515,000.00 N/A 3,498,000.00 N/A 3,767,000.00
Other Noncurrent Nonfinancial Liabilities N/A 500,000.00 N/A 500,000.00 N/A 0.00 N/A N/A
Current Liabilities N/A 72,279,000.00 N/A 84,685,000.00 N/A 79,307,000.00 N/A 94,428,000.00
Current Provisions N/A 7,181,000.00 N/A 11,241,000.00 N/A 7,855,000.00 N/A 8,165,000.00
Trade And Other Current Payables N/A N/A N/A 59,331,000.00 N/A 54,082,000.00 N/A 55,080,000.00
Trade And Other Current Payables To Trade Suppliers N/A 51,523,000.00 N/A 59,331,000.00 N/A N/A N/A N/A
Current Tax Liabilities Current N/A 1,208,000.00 N/A 1,243,000.00 N/A 1,654,000.00 N/A 2,307,000.00
Other Current Financial Liabilities N/A 9,664,000.00 N/A 10,431,000.00 N/A 13,619,000.00 N/A 27,108,000.00
Other Current Nonfinancial Liabilities N/A 302,000.00 N/A 59,000.00 N/A 0.00 N/A N/A
Line item in (eur) 01.01.2019/
01.01.2020
01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 357,398,000.00 380,240,000.00 398,557,000.00 438,754,000.00
Other Income 25,787,000.00 31,247,000.00 30,084,000.00 22,965,000.00
Changes In Inventories Of Finished Goods And Work In Progress -3,668,000.00 -2,211,000.00 10,594,000.00 7,427,000.00
Raw Materials And Consumables Used 133,656,000.00 142,614,000.00 135,566,000.00 149,312,000.00
Employee Benefits Expense 76,313,000.00 83,136,000.00 85,033,000.00 91,201,000.00
Depreciation And Amortisation Expense N/A 14,826,000.00 17,257,000.00 19,271,000.00
Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss 3,972,000.00 5,540,000.00 3,858,000.00 439,000.00
Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss 3,972,000.00 5,540,000.00 3,858,000.00 439,000.00
Other Expense By Nature 85,374,000.00 80,811,000.00 83,078,000.00 92,586,000.00
Finance Income 59,000.00 156,000.00 23,000.00 253,000.00
Finance Costs 743,000.00 2,045,000.00 312,000.00 315,000.00
Profit Loss Before Tax 74,175,000.00 84,882,000.00 92,966,000.00 101,421,000.00
Income Tax Expense Continuing Operations 10,149,000.00 11,506,000.00 10,520,000.00 11,919,000.00
Profit Loss From Continuing Operations N/A N/A 82,446,000.00 89,502,000.00
Profit (loss) -64,026,000.00 -73,376,000.00 82,446,000.00 89,502,000.00
Profit Loss Attributable To Owners Of Parent 63,962,000.00 72,549,000.00 82,390,000.00 89,550,000.00
Profit Loss Attributable To Noncontrolling Interests 64,000.00 827,000.00 56,000.00 -48,000.00
Line item in (eur) 01.01.2020 01.01.2021 02.01.2020 01.01.2022 02.01.2021 01.01.2023 02.01.2022
Profit (loss) -64,026,000.00 -73,376,000.00 N/A 82,446,000.00 N/A 89,502,000.00 N/A
Adjustments For Reconcile Profit Loss N/A N/A N/A 115,998,000.00 N/A 125,184,000.00 N/A
Adjustments For Income Tax Expense 10,149,000.00 11,506,000.00 N/A 10,520,000.00 N/A 11,919,000.00 N/A
Adjustments For Decrease Increase In Inventories N/A 717,000.00 N/A -460,000.00 N/A 1,420,000.00 N/A
Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss 3,972,000.00 5,540,000.00 N/A 3,399,000.00 N/A 0.00 N/A
Adjustments For Provisions 6,375,000.00 6,154,000.00 N/A 2,024,000.00 N/A 2,655,000.00 N/A
Adjustments For Unrealised Foreign Exchange Losses Gains N/A 1,653,000.00 N/A 50,000.00 N/A 52,000.00 N/A
Adjustments For Sharebased Payments N/A N/A N/A 0.00 N/A 146,000.00 N/A
Adjustments For Fair Value Gains Losses 313,000.00 126,000.00 N/A 46,000.00 N/A 0.00 N/A
Adjustments For Losses Gains On Disposal Of Noncurrent Assets N/A 0.00 N/A 220,000.00 N/A 439,000.00 N/A
Other Adjustments To Reconcile Profit Loss N/A 0.00 N/A -30,000.00 N/A -122,000.00 N/A
Adjustments For Reconcile Profit Loss N/A N/A N/A 115,998,000.00 N/A 125,184,000.00 N/A
Cash Flows From Used In Operations 73,130,000.00 84,445,000.00 N/A 89,085,000.00 N/A 114,182,000.00 N/A
Interest Paid Classified As Operating Activities -51,000.00 266,000.00 N/A 216,000.00 N/A 263,000.00 N/A
Income Taxes Paid Refund Classified As Operating Activities -5,494,000.00 -5,690,000.00 N/A -9,224,000.00 N/A -7,131,000.00 N/A
Other Inflows Outflows Of Cash Classified As Operating Activities N/A 0.00 N/A -59,000.00 N/A 0.00 N/A
Cash Flows From Used In Operating Activities 67,585,000.00 78,489,000.00 N/A 79,645,000.00 N/A 106,788,000.00 N/A
Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities 11,630,000.00 0.00 N/A 23,647,000.00 N/A 0.00 N/A
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities 334,000.00 385,000.00 N/A 404,000.00 N/A 7,200,000.00 N/A
Purchase Of Property Plant And Equipment Classified As Investing Activities 16,974,000.00 20,211,000.00 N/A 51,490,000.00 N/A 75,216,000.00 N/A
Purchase Of Intangible Assets Classified As Investing Activities 4,430,000.00 5,512,000.00 N/A 7,927,000.00 N/A 5,732,000.00 N/A
Interest Received Classified As Investing Activities 59,000.00 156,000.00 N/A 23,000.00 N/A 253,000.00 N/A
Cash Flows From Used In Investing Activities -34,034,000.00 -25,782,000.00 N/A -83,485,000.00 N/A -92,172,000.00 N/A
Payments To Acquire Or Redeem Entitys Shares 2,834,000.00 92,000.00 N/A 0.00 N/A N/A N/A
Payments Of Other Equity Instruments N/A N/A N/A 1,947,000.00 N/A 2,626,000.00 N/A
Proceeds From Borrowings Classified As Financing Activities -1,393,000.00 -600,000.00 N/A N/A N/A N/A N/A
Repayments Of Borrowings Classified As Financing Activities 43,922,000.00 946,000.00 N/A 1,450,000.00 N/A 0.00 N/A
Dividends Paid Classified As Financing Activities 10,338,000.00 11,544,000.00 N/A 13,719,000.00 N/A 18,147,000.00 N/A
Cash Flows From Used In Financing Activities -56,736,000.00 -14,350,000.00 N/A -17,116,000.00 N/A -18,459,000.00 N/A
Cash and cash equivalents 52,853,000.00 91,210,000.00 52,853,000.00 70,254,000.00 91,210,000.00 66,411,000.00 70,254,000.00

Please note that some sums might not add up.

Filings & Publications

2022

Report
Q1
H1
Q3
FY
Consolidated Report
ESP
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2021

Report
Q1
H1
Q3
FY
Consolidated Report
ESP
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2020

Report
Q1
H1
Q3
FY
Consolidated Report
ESP
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Sign up and we will give you access!

Capital markets information

ISIN

ES0134950F36

LEI

959800FXZQY7U3P1G969

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Bolsa de Madrid

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.